Is Silverback Therapeutics Inc (SBTX) Stock About to Get Hot Friday?

Friday, September 30, 2022 02:35 PM | InvestorsObserver Analysts

Mentioned in this article

Is Silverback Therapeutics Inc (SBTX) Stock About to Get Hot Friday?

Overall market sentiment has been high on Silverback Therapeutics Inc (SBTX) stock lately. SBTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Silverback Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SBTX!

See Full SBTX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SBTX Stock Today?

Silverback Therapeutics Inc (SBTX) stock has gained 2.08% while the S&P 500 has fallen -0.42% as of 2:34 PM on Friday, Sep 30. SBTX is higher by $0.11 from the previous closing price of $5.29 on volume of 188,906 shares. Over the past year the S&P 500 has fallen -16.84% while SBTX has fallen -48.82%. SBTX lost -$2.57 per share in the over the last 12 months. To screen for more stocks like Silverback Therapeutics Inc click here.

More About Silverback Therapeutics Inc

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Click Here to get the full Stock Report for Silverback Therapeutics Inc stock.